Skip to content
10-Q

Quarterly Report

Vanda Pharmaceuticals Inc. VNDA

0001628280-26-031667

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 60.14M sh
Shares Diluted Q1 2026 · Mar 31, 2026 59.46M sh
Shares Diluted Q1 2026 · Mar 31, 2025 58.53M sh
Capex Q1 2026 · Mar 31, 2026 $221K
Capex Q1 2026 · Mar 31, 2025 $436K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$50.22M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$33.15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $54.03M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $84.85M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $111.8M
Stockholders Equity Q1 2026 · Mar 31, 2026 $280.77M
Stockholders Equity Q1 2026 · Dec 31, 2025 $327.19M
Stockholders Equity Q1 2026 · Mar 31, 2025 $511.42M
Stockholders Equity Q1 2026 · Dec 31, 2024 $538.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $135.58M
Current Liabilities Q1 2026 · Dec 31, 2025 $145.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $152.76M
Total Liabilities Q1 2026 · Dec 31, 2025 $161.76M
Current Assets Q1 2026 · Mar 31, 2026 $293.17M
Current Assets Q1 2026 · Dec 31, 2025 $347.26M
Total Assets Q1 2026 · Mar 31, 2026 $433.53M
Total Assets Q1 2026 · Dec 31, 2025 $488.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.82
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.82
Eps Basic Q1 2026 · Mar 31, 2025 −$0.50
Sga Expense Q1 2026 · Mar 31, 2026 $68.36M
Sga Expense Q1 2026 · Mar 31, 2025 $50.08M
Rd Expense Q1 2026 · Mar 31, 2026 $28.44M
Rd Expense Q1 2026 · Mar 31, 2025 $35.71M
Net Income Q1 2026 · Mar 31, 2026 −$48.57M
Net Income Q1 2026 · Mar 31, 2025 −$29.49M
Operating Income Q1 2026 · Mar 31, 2026 −$50.22M
Operating Income Q1 2026 · Mar 31, 2025 −$41.03M
Revenue Q1 2026 · Mar 31, 2026 $51.72M
Revenue Q1 2026 · Mar 31, 2025 $50.04M